Gyre Therapeutics (GYRE) EBT (2010 - 2026)
Gyre Therapeutics (GYRE) reported EBT of -$9.2 million for Q1 2026, down 299.29% year-over-year from $4.6 million in Q1 2025, and up 53.1% on a QoQ basis from -$19.7 million in Q4 2025.
Gyre Therapeutics (GYRE) has 17 years of EBT data on file, last reported at -$9.2 million in Q1 2026.
- Quarterly EBT fell 299.29% year-over-year to -$9.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$19.1 million (down 187.14% YoY) and the FY2025 annual result came in at -$5.2 million, down 530.07% from the prior year.
- EBT improved to -$9.2 million in Q1 2026 per GYRE's latest filing, from -$19.7 million in the prior quarter.
- Across five years, EBT topped out at $51.6 million in Q2 2022 and bottomed at -$100.3 million in Q4 2023.
- The 5-year median for EBT is $3.9 million (2024), against an average of -$4.8 million.
- The widest annual swing landed in 2022, when EBT soared 359.42%; it then sank 339.82% in 2023.
- Tracing GYRE's EBT over 5 years: stood at -$22.8 million in 2022, then slumped by 339.82% to -$100.3 million in 2023, then surged by 78.82% to -$21.2 million in 2024, then rose by 7.28% to -$19.7 million in 2025, then soared by 53.1% to -$9.2 million in 2026.
- Per Business Quant, the three latest GYRE EBT figures stand at -$9.2 million (Q1 2026), -$19.7 million (Q4 2025), and $7.6 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -19.60 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -15.31 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.25 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.18 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 831.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 221.65 Mn |
| 10 | Gyre Therapeutics | 532.38 Mn | 518.25 Mn | 8.38 Mn | -9.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9.24 Mn |
| Dec 31, 2025 | -19.69 Mn |
| Sep 30, 2025 | 7.63 Mn |
| Jun 30, 2025 | 2.24 Mn |
| Mar 31, 2025 | 4.64 Mn |
| Dec 31, 2024 | -21.24 Mn |
| Sep 30, 2024 | 3.93 Mn |
| Jun 30, 2024 | 6.04 Mn |
| Mar 31, 2024 | 12.48 Mn |
| Dec 31, 2023 | -100.28 Mn |
| Sep 30, 2023 | 11.19 Mn |
| Jun 30, 2023 | 5.85 Mn |
| Mar 31, 2023 | 6.27 Mn |
| Dec 31, 2022 | -22.80 Mn |
| Sep 30, 2022 | -4.88 Mn |
| Jun 30, 2022 | 51.63 Mn |
| Mar 31, 2022 | -14.54 Mn |
| Dec 31, 2021 | -20.31 Mn |
| Sep 30, 2021 | -25.22 Mn |
| Jun 30, 2021 | -19.90 Mn |
| Mar 31, 2021 | -22.42 Mn |
| Dec 31, 2020 | -19.55 Mn |
| Sep 30, 2020 | -16.03 Mn |
| Jun 30, 2020 | -17.25 Mn |
| Mar 31, 2020 | -4.73 Mn |
| Dec 31, 2019 | -13.53 Mn |
| Sep 30, 2019 | -12.71 Mn |
| Jun 30, 2019 | -13.78 Mn |
| Mar 31, 2019 | -15.08 Mn |
| Dec 31, 2018 | -13.22 Mn |
| Sep 30, 2018 | -7.69 Mn |
| Jun 30, 2018 | -6.51 Mn |
| Mar 31, 2018 | -5.04 Mn |
| Dec 31, 2017 | -5.96 Mn |
| Sep 30, 2017 | -5.79 Mn |
| Jun 30, 2017 | -5.89 Mn |
| Mar 31, 2017 | -4.14 Mn |
| Dec 31, 2016 | -3.75 Mn |
| Sep 30, 2016 | -4.77 Mn |
| Jun 30, 2016 | -4.83 Mn |
| Mar 31, 2016 | -3.59 Mn |
| Dec 31, 2015 | -6.51 Mn |
| Sep 30, 2015 | -3.61 Mn |
| Jun 30, 2015 | -4.34 Mn |
| Mar 31, 2015 | -6.73 Mn |
| Dec 31, 2014 | -4.61 Mn |
| Sep 30, 2014 | -4.85 Mn |
| Jun 30, 2014 | -8.09 Mn |
| Mar 31, 2014 | -11.59 Mn |
| Dec 31, 2013 | -13.36 Mn |
| Sep 30, 2013 | -12.90 Mn |
| Jun 30, 2013 | -12.37 Mn |
| Mar 31, 2013 | -8.07 Mn |
| Dec 31, 2012 | -16.03 Mn |
| Sep 30, 2012 | -7.88 Mn |
| Jun 30, 2012 | 14.49 Mn |
| Mar 31, 2012 | 2.26 Mn |
| Dec 31, 2011 | -9.81 Mn |
| Sep 30, 2011 | -9.05 Mn |
| Jun 30, 2011 | -2.26 Mn |
| Mar 31, 2011 | 12.59 Mn |
| Dec 31, 2010 | -1.03 Mn |
| Sep 30, 2010 | 2.74 Mn |
| Jun 30, 2010 | 5.29 Mn |